Skip to Main Content

Paper Details

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.
Oncotarget
20
2018
/, AKT, AML, APL, ATO, Acute myeloid leukemia, Arsenic trioxide, As2O3, ERK, FLT3, FLT3 RNA, FLT3 protein, FLT3 tyrosine kinase, FLT3/, FLT3/ITD, FLT3/ITD+, FLT3/ITD+ cells, FLT3/ITD+ leukemia cells, FLT3/ITD+ leukemias, HOXA9, ITD, ITD+, MEIS1, STAT5, USP10, acute promyelocytic leukemia, hematologic malignances, leukemia, leukemias, patient, patients, sorafenib, tyrosine, wild, wild-type FLT3, wild-type FLT3 leukemia cells
Author NameAffiliation
Li LiJohns Hopkins University School of Medicine
Li LiJohns Hopkins University School of Medicine
Mark J LevisJohns Hopkins University School of Medicine
Mark J LevisJohns Hopkins University School of Medicine
Donald SmallJohns Hopkins University School of Medicine
Donald SmallJohns Hopkins University School of Medicine
Donald SmallJohns Hopkins University School of Medicine
Donald SmallJohns Hopkins University School of Medicine
  • 1 - 8

Datasets

Release 1.2